< Back to previous page


Cardiovascular diseases (CARDIOVASC)

Research group

Lifecycle:1 Jan 2019 →  Today
Organisation profile:Currently active lines of resarch are: - Clinical evaluation of percutaneous treatment modalities for structural heart diseases, and prognostic stratification of patients who are candidate for or who are undergoing structural heart interventions (TAVI; MitraClip; …); - Study of ischemia-reperfusion injury during acute myocardial infarction with identification of underlying pathophysiological mechanisms and with the development and the testing of potential treatment strategies that could prevent/attenuate the reperfusion injury; - Study of biomarkers in cardiology aiming at improving the diagnosis and treatment of several cardiovascular diseases, such as acute coronary syndromes, heart failure, heart transplantation. - individualised patient and family management for cardiogenetic conditions, including individualised in vitro expression of mutations and characterisation of phenotypic expression in standard cell lines or in induced pluripotent stem cells (iPSC) - individualised ablation approach for patients with persistent atrial fibrillation, based on novel mapping and ablation strategies, combining both substrate and functional measures (like fibrosis mapping + rotor mapping). - innovative care pathways for optimised care for patients with atrial fibrillation (AF) through the setup of a multidisciplinary AF clinic, studying the impact of different closed loop pathways (e.g. tailored education; e.g. mHealth education; e.g. PROM assessment; e.g. adherence tele monitoring for NOAC patients; …) - sports cardiology research, focusing both on younger athletes (e.g. epigenetics of ARVC; creation of a EU registry on athletes with LV scarring; e.g. characterisation of arrhythmia subforms in athletes) and master athletes (e.g. long-term changes in the sports heart; e.g. prevalence of subclinical coronary atheromathosis and peripheral vascular dysfunction) - heart failure with combined in vitro and in vivo evaluation of endothelial dysfunction, epigenetics studies, hemodynamics, and studies on the effect of exercise/rehabilitation, both in patients with reduced and preserved LV ejection fraction (HFrEF and HFpEF) - evaluation, management and follow-up of patients with grown-up congenital heart disease, studying specific prognostic markers, multidisciplinary care needs and effect of cardiac rehabilitation - Invasive evaluation and treatment of coronary artery disease: prospective physiologic evaluation of left main (PHYNAL), spontaneous coronary artery dissections (SCAD), invasive support in cardiogenic shock, novel stent platforms and treatment of chronic total occlusions (CTO) in patients with persistent ischemia/angina.
Disciplines:Cardiac and vascular medicine, Public health services, Nursing, Rehabilitation sciences, Biomarker discovery and evaluation, Drug discovery and development, Pharmacotherapy